Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)
NCT01381536
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG:
GSK1550188 1mg/kg or 10mg/kg
Sponsor
GlaxoSmithKline